TLDR
- Novo Nordisk will manufacture Wegovy weight loss pills at its Athlone, Ireland facility for markets outside the US
- The pill version launched in early January attracted over 240,000 American users and tracked 38,220 prescriptions in its fifth week
- CEO Mike Doustdar called the pill launch “one of the most successful pharmaceutical debuts ever”
- Novo hopes the pill will help reclaim market share lost to rival Eli Lilly’s Zepbound drug
- The company warned of up to 13% sales decline this year due to an intensifying price war in obesity drugs
Novo Nordisk announced plans to expand its Athlone, Ireland facility to produce Wegovy weight loss pills for international markets. The move comes as the Danish drugmaker fights to regain ground in the obesity drug market.
Novo Nordisk is expanding Wegovy pill production in Ireland.
The Athlone facility will support global markets outside the U.S. a major move amid soaring demand for obesity medications.
Full breakdown + infographic
🔗 https://t.co/OB6L7Ysdab#Wegovy #NovoNordisk #GLP1 pic.twitter.com/viWmUvfSkh— Vivian Taylor (@unfunnymom453) February 13, 2026
CEO Mike Doustdar described the January pill launch as “one of the most successful pharmaceutical debuts ever.” More than 240,000 Americans have already started taking the medication.
IQVIA data showed Wegovy pills hit 38,220 U.S. prescriptions in the fifth week after launch. The strong uptake signals growing consumer preference for oral medication over injections.
Novo acquired the Athlone plant from Alkermes in 2024 for €85 million. The facility previously operated as Elan Drug Technologies.
The company will produce Wegovy pills for non-U.S. markets in Ireland. American supplies come from domestic manufacturing sites.
“If we were about to throw in the towel, we would not be investing in factories in Ireland,” Doustdar said. He suggested the pill version could eventually surpass injectable Wegovy in popularity.
Battle for Market Share
Novo faces stiff competition from Eli Lilly’s Zepbound. The Danish company once dominated the weight loss drug market but has lost share to its American rival.
The company recently announced plans to offer Wegovy in vial form. This matches Lilly’s product lineup of injectables, vials, and pills.
Last week Novo warned investors of a potential 13% sales decline this year. The forecast sent shares down 20%.
An intensifying price war has pressured profit margins. The Trump administration has pushed for lower obesity drug prices.
Novo cut 9,000 jobs worldwide last year. The Athlone facility lost up to 75 positions from a workforce of 400.
Pricing Controversy
The company priced Wegovy pills at $149 per prescription. U.S. company Hims & Hers Health said it would sell a version for just $49.
The Food and Drug Administration warned Hims & Hers to stop. The dispute highlights ongoing debates about drug pricing and competition.
Two years ago Novo abandoned plans for a factory near Dublin. The new Athlone investment shows renewed commitment to Irish manufacturing.
Ireland serves as a pharmaceutical hub for global companies. Eli Lilly produces active ingredients for its weight loss drugs there.
Doustdar declined to specify the investment amount for the Athlone expansion. The facility will focus on serving international markets outside the United States.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
